You are currently viewing the abstract.
View Full TextAbstract
Combining BCL-2 inhibitor venetoclax with monoclonal CD20 antibody rituximab greatly enhances progression-free survival compared with bendamustine-rituximab in a phase 3 trial of relapsed or refractory chronic lymphocytic leukemia patients.
- Copyright © 2018, American Association for the Advancement of Science